519 related articles for article (PubMed ID: 20962708)
1. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Delattre IK; Musuamba FT; Jacqmin P; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq P
Clin Biochem; 2012 Jul; 45(10-11):780-6. PubMed ID: 22503878
[TBL] [Abstract][Full Text] [Related]
3. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE
Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
6. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
7. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
[TBL] [Abstract][Full Text] [Related]
8. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
Min Y; Qiang F; Peng L; Zhu Z
Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
[TBL] [Abstract][Full Text] [Related]
9. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study].
Reimann IR; Meier-Hellmann A; Pfeifer R; Traut T; Schilling A; Stein G; Reinhart K; Hoffmann A
Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):288-95. PubMed ID: 10372218
[TBL] [Abstract][Full Text] [Related]
10. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS
J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185
[TBL] [Abstract][Full Text] [Related]
11. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
Lugo G; Castañeda-Hernández G
Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation.
Saint-Marcoux F; Debord J; Undre N; Rousseau A; Marquet P
Ther Drug Monit; 2010 Apr; 32(2):129-35. PubMed ID: 20110850
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of amikacin in geriatric patients studied with the NPEM-2 algorithm.
Debord J; Charmes JP; Marquet P; Merle L; Lachâtre G
Int J Clin Pharmacol Ther; 1997 Jan; 35(1):24-7. PubMed ID: 9021438
[TBL] [Abstract][Full Text] [Related]
14. [Can we use a Bayesian method to build a pharmacokinetic population in two steps?].
Cabelguenne D; Bleyzac N; Pivot C; Maire P
Therapie; 2000; 55(2):277-82. PubMed ID: 10967700
[TBL] [Abstract][Full Text] [Related]
15. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
[TBL] [Abstract][Full Text] [Related]
17. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of population pharmacokinetics with NONMEM in clinical patients treated with amikacin by intravenous infusion].
Chu XM; Rui JZ; Zhou YG; Dai YJ; Cai WM; Ling SS
Yao Xue Xue Bao; 1996; 31(12):881-5. PubMed ID: 9863218
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
